Beam Therapeutics Inc. (BEAM) Financials

BEAM Assets vs Liabilities
DateAssetsLiabilities
March 31, 2026 1.5 billion 316.4 million
Dec. 31, 2025 1.5 billion 242.8 million
Sept. 30, 2025 1.3 billion 345.1 million
June 30, 2025 1.4 billion 344.3 million

BEAM Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
March 31, 2026 -130.7 million 19.0 million
Dec. 31, 2025 -87.0 million -73.8 million
Sept. 30, 2025 -86.5 million 22.7 million
June 30, 2025 -79.6 million 24.4 million

BEAM Net Income

No data available :(

BEAM Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
March 31, 2026 1.2 billion 100.2 million 150.6 million
Dec. 31, 2025 1.2 billion 139.8 million 139.8 million
Sept. 30, 2025 1.1 billion - 151.4 million
June 30, 2025 1.2 billion - 154.8 million

BEAM Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
March 31, 2026 103.3 million
Dec. 31, 2025 104.9 million
Sept. 30, 2025 102.6 million
June 30, 2025 102.0 million

BEAM Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
March 31, 2026 2.2 million 104.5 million 34.4 million -
Dec. 31, 2025 3.7 million 99.3 million 26.6 million -
Sept. 30, 2025 5.0 million 109.8 million 26.7 million -
June 30, 2025 3.1 million 101.8 million 26.9 million -

BEAM Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
March 31, 2026 31.7 million 5.6 million
Dec. 31, 2025 114.1 million 5.7 million
Sept. 30, 2025 9.7 million 109.8 million
June 30, 2025 8.5 million 101.8 million

BEAM

Price: $32.83

52 week price:
15.35
36.44

Payout Ratio Range:
-45.65%
-4.19%

Earnings Per Share: -0.49 USD

Exchange: NMS

Sector: Healthcare

Industry: Biotechnology

Country: United States

Volume: 1.0 million

Market Capitalization: 2.9 billion

Links: